polatuzumab fda approval in dlbcl (polarix) & swog s1826 nivo vs. bv in hodgkin's lymphoma
Published 1 year ago • 2.4K plays • Length 21:26Download video MP4
Download video MP3
Similar videos
-
0:41
results of swog s1826 study, showing nivo-avd better than bv-avd in hodgkin's lymphoma patients
-
0:43
summary of two important lymphoma studies - polarix andd swog s1826 #oncology #cancer #lymphoma
-
0:55
swog s1826 study design discussion in hodgkin's lymphoma patients #oncology #cancer #2023
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
0:46
dlbcl prognosis & management in front-line settings #oncology #lungcancer #cancer #2023
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
43:40
polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma.
-
6:45
nivolumab chemotherapy in previously untreated stage iii or iv hodgkin lymphoma
-
1:52
dr. diefenbach on polatuzumab vedotin plus obinutuzumab and lenalidomide in fl
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
4:47
the polarix trial: initial therapy of diffuse large b-cell lymphoma
-
1:35
dr. pagel on the implications of polatuzumab vedotin approval in dlbcl
-
6:50
nivolumab-avd improved pfs versus brentuximab vedotin-avd in patients with advanced stage hl
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
1:14
brentuximab vedotin combined with nivolumab for hodgkin lymphoma
-
3:12
polarix: polatuzumab vedotin and r-chp superior to r-chop in dlbcl
-
2:30
new lymphoma drug studies show promise
-
1:36
possibilities for the use of pembrolizumab in lymphoma treatment
-
1:57
the current hodgkin lymphoma immunotherapy landscape